AI assistant
SYNTARA LIMITED — Investor Presentation 2021
Oct 24, 2021
65830_rns_2021-10-24_c1a9cca7-36b4-41d2-9ba5-e1ef321b1596.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [154 x 45] intentionally omitted <==
Media Release
25 October 2021
PHARMAXIS QUARTERLY SHAREHOLDER UPDATE
AND INVESTOR BRIEFING
Thursday 28 October 2021 at 1.00pm
Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 28 October 2021.
Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 1.00pm AET on Thursday 28 October 2021.
The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.
The event is free to attend, and investors should register in advance using the following registration link:
‐ ‐ https://www.pharmaxis.com.au/investor centre/investor briefing/
Upon registration, instructions for joining the session will be sent via email.
To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre‐submit questions by emailing them to: [email protected]
#ENDS#
SOURCE: Pharmaxis Ltd, Sydney, Australia
AUTHORISED FOR RELEASE TO ASX BY:
Pharmaxis Ltd Disclosure Committee. Contact: David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E [email protected]
CONTACT:
Media: Felicity Moffatt: T +61 418 677 701, E [email protected] Investor Relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737, E [email protected]
Join the Pharmaxis mailing list here
Follow us:
==> picture [20 x 20] intentionally omitted <==
==> picture [20 x 19] intentionally omitted <==
About Pharmaxis
Pharmaxis Ltd is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the
Page 1 of 2
chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.
Pharmaxis is developing its drug PXS‐5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS‐5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that commenced recruitment in Q1 2021. PXS‐5505 is also being investigated as a potential treatment for other cancers such as glioblastoma, liver and pancreatic cancer.
Other drug candidates being developed from Pharmaxis’ amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases such as Duchenne Muscular Dystrophy.
Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, which is approved and marketed in the United States, Europe, Russia and Australia; and Aridol® for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia.
Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. www.pharmaxis.com.au
Forward‐Looking Statements
Forward‐looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward‐looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward‐looking statements. These forward‐looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward‐looking statements as a result of new information, future events or otherwise.
Page 2 of 2